Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.
The booster dose of the Pfizer–BioNTech COVID-19 vaccine should not be delayed in people with cancer, suggest the results of two studies showing insufficient immunogenicity with just the first dose.
The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.
An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.
Pembrolizumab monotherapy can achieve responses lasting for more than a year in some patients with previously treated malignant pleural mesothelioma (MPM), suggest phase 2 trial data.
Women with hormone receptor-positive, HER2-negative metastatic breast cancer derive a significant progression-free survival benefit from the addition of alisertib to paclitaxel, indicate phase 2 trial findings.
Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.
An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.
The majority of patients with cancer and their physicians report a preference for in-person visits rather than telemedicine consultations, suggest results of a survey carried out at the start of the COVID-19 pandemic.
The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.
Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.
Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.
Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.
The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.
Measuring plasma cell-free DNA integrity could improve the accuracy of MRI for predicting a complete response to neoadjuvant chemotherapy for locally advanced breast cancer, research suggests.